# Bluejay Diagnostics, Inc.: overview

BJDX · Nasdaq · CIK 1704287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bjdx.md) · [Financials](/companies/bjdx/financials.md) · [Filings](/companies/bjdx/filings.md) · [Insiders](/companies/bjdx/insiders.md)

Latest reported revenue: [$0](/filings/0001213900-24-027305.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 28, 2024 (XBRL us-gaap:Revenues, accession 0001213900-24-027305).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(76.94)](/filings/0001213900-25-107599.md) | not reported | [(13.46)](/filings/0001213900-26-053328.md) | [(5.64)](/filings/0001213900-26-088347.md) | [(1.01)](/filings/0001213900-25-107599.md) | not reported | [(1.95)](/filings/0001213900-26-053328.md) | [(1.12)](/filings/0001213900-26-088347.md) |
| Free cash flow | $k | [(2,155) d](/filings/0001213900-25-107599.md) | [(1,452) d](/filings/0001213900-26-024616.md) | not reported | not reported | not reported | not reported | [(1,608)](/filings/0001213900-26-053328.md) | [(1,642) d](/filings/0001213900-26-088347.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [249](/filings/0001213900-24-027305.md) | not reported | not reported | not reported |
| Gross margin | % | not reported | [19.6%](/filings/0001213900-24-027305.md) | not reported | not reported | not reported |
| Operating margin | % | not reported | [(3741.5%)](/filings/0001213900-24-027305.md) | not reported | not reported | not reported |
| Net margin | % | not reported | [(3733.1%)](/filings/0001213900-24-027305.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.41)](/filings/0001213900-23-021454.md) | [(9.22)](/filings/0001213900-24-027305.md) | [(3631.48)](/filings/0001213900-25-026275.md) | [(456.75)](/filings/0001213900-26-024616.md) | [(15.25)](/filings/0001213900-26-024616.md) |
| Free cash flow | $k | [(4,391)](/filings/0001213900-23-021454.md) | [(8,941)](/filings/0001213900-24-027305.md) | [(9,018)](/filings/0001213900-25-026275.md) | [(8,128)](/filings/0001213900-26-024616.md) | [(6,227)](/filings/0001213900-26-024616.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bjdx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $157.2k | 131,000 |  | New +131,000 |
| [HEIGHTS CAPITAL MANAGEMENT, INC](/funds/1081698.md) | 2026-06-30 | $42.5k | 35,400 |  | New +35,400 |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $32.6k | 27,130 |  | New +27,130 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $12.4k | 10,337 |  | New +10,337 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $12.3k | 10,225 |  | New +10,225 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.3k | 1,907 |  | Added +178 |
| [L1 Global Manager Pty Ltd](/funds/1878742.md) | 2026-06-30 | $144 | 120 |  | Unchanged |
| [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $1 | 1 |  | Reduced −2 |

## Recent filings

[All 244 filings](/companies/bjdx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 13:09 ET | [8-K](/filings/0001213900-26-108779.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-108779 |
| 2026-10-06 | 13:04 ET | [8-K](/filings/0001213900-26-106999.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-106999 |
| 2026-09-08 | 20:50 ET | [8-K](/filings/0001213900-26-098071.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-098071 |
| 2026-08-13 | 11:56 ET | [8-K](/filings/0001213900-26-088701.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-088701 |
| 2026-08-12 | 20:05 ET | [10-Q](/filings/0001213900-26-088347.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088347 |
| 2026-07-22 | 21:25 ET | [8-K](/filings/0001213900-26-080474.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-080474 |
| 2026-06-09 | 21:26 ET | [8-K](/filings/0001213900-26-066896.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-066896 |
| 2026-06-08 | 21:15 ET | [8-K](/filings/0001213900-26-066364.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-066364 |
| 2026-06-02 | 01:00 ET | [SCHEDULE 13D/A](/filings/0001213900-26-064363.md) | Ownership report, active investor, amended | 0001213900-26-064363 |
| 2026-06-02 | 00:10 ET | [SCHEDULE 13D/A](/filings/0001213900-26-064352.md) | Ownership report, active investor, amended | 0001213900-26-064352 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-024616.md), filed Mar 6, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1704287
- Tickers: BJDX
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.